[{"data":1,"prerenderedAt":190},["ShallowReactive",2],{"drug-mmr-vaccine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":35,"contraindications":72,"warnings":89,"renal":90,"monitoring":91,"interactions":92,"review":93,"examples":96,"atc":106,"iran":108,"links":136,"populations":151,"usApproval":185},"mmr-vaccine",1,{"fa":7,"en":8},"واکسن سرخک، اوریون و سرخجه (MMR)","MMR vaccine (measles, mumps, rubella)","anti-infectives",{"fa":11,"en":12},"واکسن زنده ضعیف‌شده","Live attenuated vaccine",[14],{"name":15,"market":16},"M-M-R II","US",[18,19,20,21],"mmr","ام ام آر","واکسن سرخک","priorix",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":30,"refs":31},"vial-05","injection","im","0.5 mL dose after reconstitution",{"amount":5,"unit":29,"perVolumeMl":5},"mL",[16],[32],{"source":33,"section":34},"fda-mmr","3",[36,60],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":29,"dose":47,"refs":49,"durationDays":52,"notes":53},"std","immunization",{"fa":40,"en":41},"دو دوز ۰٫۵ mL — ۱۲ تا ۱۵ ماهگی و ۴ تا ۶ سالگی","Two 0.5 mL doses — at 12–15 months and 4–6 years",{"minAge":43},{"value":44,"unit":45},12,"month","fixed",{"perDose":48,"dosesPerDay":5},0.5,[50],{"source":33,"section":51},"2.1",{"min":5,"max":5},[54],{"text":55,"refs":58},{"fa":56,"en":57},"دوز دوم پیش از ۴ سالگی هم مجاز است اگر دست‌کم ۱ ماه فاصله باشد. پیشگیری پس از تماس با سرخک: یک دوز ظرف ۷۲ ساعت. عضلانی یا زیرجلدی.","The second dose may be given before 4 y if at least 1 month apart. Measles post-exposure: one dose within 72 h. IM or SC.",[59],{"source":33,"section":51},{"id":61,"disease":62,"label":63,"population":66,"type":46,"unit":29,"dose":68,"refs":69,"durationDays":71},"measles-pep","measles",{"fa":64,"en":65},"پیشگیری پس از تماس با سرخک — یک دوز ظرف ۷۲ ساعت","Measles post-exposure prophylaxis — one dose within 72 h",{"minAge":67},{"value":44,"unit":45},{"perDose":48,"dosesPerDay":5},[70],{"source":33,"section":51},{"min":5,"max":5},[73,82],{"id":74,"severity":75,"text":76,"refs":79},"live","block",{"fa":77,"en":78},"بارداری، نقص ایمنی، بیماری تب‌دار متوسط تا شدید، سل فعال درمان‌نشده (واکسن زنده).","Pregnancy, immunosuppression, moderate or severe febrile illness, active untreated tuberculosis (live vaccine).",[80],{"source":33,"section":81},"4",{"id":83,"severity":75,"text":84,"refs":87},"allergy",{"fa":85,"en":86},"واکنش آلرژیک شدید به اجزای واکسن (از جمله ژلاتین و نئومایسین) یا دوز قبلی.","Severe allergic reaction to a vaccine component (including gelatin and neomycin) or a previous dose.",[88],{"source":33,"section":81},[],[],[],[],{"status":94,"reviewer":95,"date":95},"unverified",null,[97,101],{"regimen":37,"formulation":24,"input":98,"expect":100},{"ageYears":5,"weightKg":99},10,{"perDose":48,"mlPerDose":48},{"regimen":61,"formulation":24,"input":102,"expect":105},{"ageYears":103,"weightKg":104},3,14,{"perDose":48,"mlPerDose":48},[107],"J07BD52",{"status":109,"forms":110,"refs":131},"registered",[111,115,119,123,127],{"code":112,"en":113,"fa":114},"01578","VACCINE-MEASLES+MUMPS+RUBELLA VIRUS 10DOSE VIAL","ویال واکسن–سرخک + اوریون + سرخجه ویروس ۱۰ دوز",{"code":116,"en":117,"fa":118},"07629","VACCINE-MEASLES+MUMPS+RUBELLA VIRUS 1DOSE VIAL","ویال واکسن–سرخک + اوریون + سرخجه ویروس ۱ دوز",{"code":120,"en":121,"fa":122},"09575","VACCINE-MEASLES+MUMPS+RUBELLA VIRUS 2DOSE VIAL","ویال واکسن–سرخک + اوریون + سرخجه ویروس ۲ دوز",{"code":124,"en":125,"fa":126},"01990","VACCINE-MEASLES+RUBELLA (10 dose) VIAL","ویال واکسن–سرخک + سرخجه (۱۰ دوز)",{"code":128,"en":129,"fa":130},"50415","MEASLES \u002F MUMPS \u002F RUBELLA VACCINE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PARENTERAL 5 {dose} 2.5 mL","محلول تزریقی واکسن سرخک \u002F اوریون \u002F سرخجه ۵ { دوز } ۲٫۵ میلی‌لیتر",[132],{"source":133,"section":134,"url":135},"darooyab-generic","G-3486\u002FMeasles,-Mumps,-and-Rubella-Vaccines","https:\u002F\u002Fwww.darooyab.ir\u002FG-3486\u002FMeasles,-Mumps,-and-Rubella-Vaccines",[137,141,145,148],{"kind":138,"url":139,"label":140},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=101069","BLA101069",{"kind":142,"url":143,"label":144},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0a9e384f-e717-436b-b9a0-15e53cef0862","FDA M-M-R II",{"kind":146,"url":147,"label":107},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J07BD52",{"kind":149,"url":135,"label":150},"darooyab","Measles,-Mumps,-and-Rubella-Vaccines",{"pregnancy":152,"lactation":160,"pediatric":169,"geriatric":177},{"level":153,"text":154,"quote":157,"refs":158},"contraindicated",{"fa":155,"en":156},"برچسب: در بارداری منع مصرف دارد.","Label: contraindicated in pregnancy.","( 4.4 ) Pregnancy.",[159],{"source":33,"section":81},{"level":161,"text":162,"quote":165,"refs":166},"caution",{"fa":163,"en":164},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Studies have shown that lactating postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants. { 17 , 18 } In the breast-fed infants with serological evidence of rubella virus vaccine strain antibodies, none exhibited severe disease; …",[167],{"source":33,"section":168},"8.2",{"level":161,"text":170,"quote":173,"refs":174},{"fa":171,"en":172},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of measles vaccine in infants below the age of 6 months have not been established [see Clinical Studies (14) ] .",[175],{"source":33,"section":176},"8.4",{"level":161,"text":178,"quote":181,"refs":182},{"fa":179,"en":180},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of M-M-R II did not include sufficient numbers of seronegative subjects aged 65 and over to determine whether they respond differently from younger subjects.",[183],{"source":33,"section":184},"8.5",{"kind":186,"refs":187,"id":140},"BLA",[188],{"source":33,"section":189},"SPL approval \u002F marketing category",1792191874950]